KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Research & Development: 2009-2024

Historic Research & Development for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $1.1 billion.

  • Alnylam Pharmaceuticals' Research & Development rose 32.44% to $358.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 13.62%. This contributed to the annual value of $1.1 billion for FY2024, which is 12.13% up from last year.
  • Alnylam Pharmaceuticals' Research & Development amounted to $1.1 billion in FY2024, which was up 12.13% from $1.0 billion recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Research & Development high stood at $1.1 billion for FY2024, and its period low was $654.8 million during FY2020.
  • Its 3-year average for Research & Development is $1.0 billion, with a median of $1.0 billion in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first dropped by 0.05% in 2020, then increased by 20.97% in 2021.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Research & Development stood at $654.8 million in 2020, then rose by 20.97% to $792.2 million in 2021, then grew by 11.47% to $883.0 million in 2022, then rose by 13.75% to $1.0 billion in 2023, then increased by 12.13% to $1.1 billion in 2024.